Roth Sees Regeneron/Sanofi Alirocumab Phase 2 Results as Positive; Maintains 'Buy' Rating (REGN)
Tweet Send to a Friend
Roth Capital affirms Regeneron Pharmaceuticals (Nasdaq: REGN) at Buy with a $382 price target.
Earlier, Sanofi and Regeneron Pharma ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Earlier, Sanofi and Regeneron Pharma ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
